Journal of Diabetology

ORIGINAL ARTICLES
Year
: 2020  |  Volume : 11  |  Issue : 3  |  Page : 175--182

Evaluation of type 2 diabetes treatment with gliclazide modified release in Azerbaijan (the EdiAzer study): Results from a 16-week observational clinical study


Valeh A Mirzazada1, Ramila A Huseynova1, Sevil A Mustafayeva1, Fidan N Gasimova1, Ulviyya Ahmadova2, Narmin Ismayilova2, Vafa Kerimova2, Hagigat Mehdiyeva3, Rana Suleymanova4, Zahrakhanim Maharramova4, Gulnara Iskandarli5, Ofeliya Gurbanova6, Sariyya Aghayeva2, Sabina Malikova7, Konul Ismayilova8, Khanim Salimkhanova9 
1 Azerbaijan State Institute for Physician Postgraduate Education, Baku, Azerbaijan
2 Republic Endocrinology Center, Baku, Azerbaijan
3 City Polyclinic No. 24, Baku, Azerbaijan
4 Central Hospital for Oil Workers, Baku, Azerbaijan
5 Nasraddin Tusi Clinic, Baku, Azerbaijan
6 City Polyclinic No. 34, Baku, Azerbaijan
7 Starlab Private Medical Center, Baku, Azerbaijan
8 Azerbaijani Medical University, Baku, Azerbaijan
9 Baku Private Clinic, Baku, Azerbaijan

Correspondence Address:
Dr. Valeh A Mirzazada
Azerbaijan State Institute for Physician Postgraduate Education, Baku.
Azerbaijan

Introduction: Type 2 diabetes is a major public health problem across all economic regions. This open-label study collected real-world data on patients presenting with type 2 diabetes in Azerbaijan treated with gliclazide modified release (MR). Materials and Methods: Newly-diagnosed patients uncontrolled by diet, and patients uncontrolled by metformin were prescribed gliclazide MR 60mg (30–120mg/day) for 16 weeks. Primary study endpoints were changes in mean glycated hemoglobin A1c (HbA1c) and percentage of participants achieving HbA1c ≤7.0% and/or an HbA1c improvement ≥1.0%. Secondary endpoints included changes in mean fasting plasma glucose (FPG) and weight. Serious adverse events were monitored throughout the study. Results: Data from 105 patients were available for analysis. Mean age was 55.1 ± 10.4 years, 53.3% were female and 82.9% were overweight or obese. Mean duration of diabetes was 2.3 ± 2.6 years. A total of 44 patients were receiving metformin before study entry. At W0, 61 patients (58.1%) were prescribed gliclazide MR monotherapy, and 44 (41.9%) were prescribed gliclazide MR in combination with the metformin. At the end of the study, a statistically significant decrease was observed in mean HbA1c levels from 8.8% ± 1.4% to 7.6% ± 1.0% (P < 0.001). In addition, 30 (28.6%) patients achieved an HbA1c <7.0% (P < 0.0001), and 61 (58.1%) an HbA1c reduction of ≥1.0%. Reductions in FPG levels were statistically significant compared with baseline from week 2 onward. No weight gain was observed, and there were no serious adverse events, including no reports of severe hypoglycemia. Conclusion: Gliclazide MR is an effective and well-tolerated first- or second-line agent in type 2 diabetes and may be particularly valuable in low-to-middle income countries where therapeutic options are limited by accessibility and cost.


How to cite this article:
Mirzazada VA, Huseynova RA, Mustafayeva SA, Gasimova FN, Ahmadova U, Ismayilova N, Kerimova V, Mehdiyeva H, Suleymanova R, Maharramova Z, Iskandarli G, Gurbanova O, Aghayeva S, Malikova S, Ismayilova K, Salimkhanova K. Evaluation of type 2 diabetes treatment with gliclazide modified release in Azerbaijan (the EdiAzer study): Results from a 16-week observational clinical study.J Diabetol 2020;11:175-182


How to cite this URL:
Mirzazada VA, Huseynova RA, Mustafayeva SA, Gasimova FN, Ahmadova U, Ismayilova N, Kerimova V, Mehdiyeva H, Suleymanova R, Maharramova Z, Iskandarli G, Gurbanova O, Aghayeva S, Malikova S, Ismayilova K, Salimkhanova K. Evaluation of type 2 diabetes treatment with gliclazide modified release in Azerbaijan (the EdiAzer study): Results from a 16-week observational clinical study. J Diabetol [serial online] 2020 [cited 2020 Oct 30 ];11:175-182
Available from: https://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2020;volume=11;issue=3;spage=175;epage=182;aulast=Mirzazada;type=0